← All stocks

Mineralys Therapeutics, Inc.

MLYS Scheduled selling only
CIK 0001933414 #1952 in the set updated 17 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$193.19K
$0.00 on a plan · $193.19K straight out of an exercise
Sold at will
$0.00
0 of 1 sales
Net
−$193.19K
$0.00 against sales at will

By person

13 insiders · 1 transaction
24.6×

Jon Congleton holds 24.6 times base salary in stock. $15.68M of shares against $636.50K in salary for 2025.

Salary from the company's own proxy. The shares are what Jon Congleton last reported holding, valued at $25.98, the price Common Stock was last bought or sold at on the open market here, on 21 Aug 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Warren Eric
Chief Commercial Officer
$193.19K (1) scheduled
−$193.19K
38,400
0.0434%
$997.51K
0.0%
Slingsby Brian Taylor
Director
7,910,038
8.95%
$205.48M
−8.5%
RA CAPITAL MANAGEMENT, L.P. entity
Director
5,825,521
6.59%
$151.33M
+95.6%
Samsara BioCapital GP, LLC entity
10% owner
5,674,916
6.42%
$147.42M
+11.8%
Congleton Jon
Chief Executive Officer
603,621
0.6828%
$15.68M
−33.8%
AKKARAJU SRINIVAS
Director
594,435
0.6724%
$15.44M
Ferguson James J. III
Chief Medical Officer
102,400
0.1158%
$2.66M
Rodman David Malcom
Chief Medical Officer
51,384
0.0581%
$1.33M
−60.2%
Levy Adam Scott
CFO and Secretary
48,538
0.0549%
$1.26M
−69.8%
Karydas Daphne
Director
6,200
0.0070%
$161.06K
SBLENDORIO GLENN
Director
6,200
0.0070%
$161.06K
Gold Alexander M
Director
6,200
0.0070%
$161.06K
DiRocco Derek
Director
6,200
0.0070%
$161.06K

Nothing of that kind in this period.

What was left out

Form 4 filings counted 1
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 1
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 7,437
History held since 13 Feb 2023